{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:53:54Z","timestamp":1790394834125,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006282.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000}}],"reference-count":285,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006282.pub5","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T08:48:42Z","timestamp":1580719722000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Drug treatment for spinal muscular atrophy types II and III"],"prefix":"10.1002","author":[{"given":"Renske I","family":"Wadman","sequence":"first","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Ludo","family":"van der Pol","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy MJ","family":"Bosboom","sequence":"additional","affiliation":[{"name":"Onze Lieve Vrouwe Gasthuis locatie West; Department of Neurology; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay-Lynn","family":"Asselman","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H","family":"van den Berg","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T","family":"Iannaccone","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center; Department of Pediatrics; 5323 Harry Hines Boulevard Dallas Texas USA 75390"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander FJE","family":"Vrancken","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"513-22. Correct","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0002|cit2","unstructured":"NCT01302600 Safety and efficacy of olesoxime (TRO19622) in 3-25 years SMA patients clinicaltrials.gov\/ct2\/show\/NCT01302600"},{"issue":"24","key":"10.1002\/14651858.CD006282.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.0b013e3182020332","article-title":"Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy","volume":"75","author":"Chen","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0004|cit4","unstructured":"NCT00485511 A trial of hydroxyurea in spinal muscular atrophy clinicaltrials.gov\/ct2\/show\/NCT00485511"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","article-title":"Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study","volume":"24","author":"Kirschner","year":"2014","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0006|cit6","unstructured":"NCT00533221 Pilot study of growth hormone to treat SMA type II and III clinicaltrials.gov\/ct2\/show\/NCT00533221"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.23904","article-title":"SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy","volume":"49","author":"Kissel","year":"2014","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0008|cit8","unstructured":"NCT00481013 Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA) clinicaltrials.gov\/ct2\/show\/NCT00481013"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0011|cit11","unstructured":"NCT02292537 A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later-onset spinal muscular atrophy (SMA) (CHERISH) clinicaltrials.gov\/ct2\/show\/NCT02292537"},{"issue":"1-2","key":"10.1002\/14651858.CD006282.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0013|cit13","unstructured":"NCT00227266 Valproic acid and carnitine in patients with spinal muscular atrophy clinicaltrials.gov\/ct2\/show\/study\/NCT00227266"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PloS One"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00002060-200009000-00005","article-title":"A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report","volume":"79","author":"Tzeng","year":"2000","journal-title":"American Journal of Physical Medicine & Rehabilitation"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CND.0b013e3180315c99","article-title":"A randomized, placebo-controlled trial of creatine in children with spinal muscular atrophy","volume":"8","author":"Wong","year":"2007","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2125.2010.03843.x","article-title":"Riluzole pharmacokinetics in young patients with spinal muscular atrophy","volume":"71","author":"Abbara","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2005","journal-title":"European Journal of Human Genetics"},{"issue":"6","key":"10.1002\/14651858.CD006282.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0020|cit20","unstructured":"Chang JG Tsai FJ Wang WY Jong YJ Treatment of spinal muscular atrophy by hydroxyurea American Journal of Human Genetics 2002 2402"},{"issue":"10","key":"10.1002\/14651858.CD006282.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-11-36","article-title":"Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid","volume":"11","author":"Darbar","year":"2011","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0023|cit23","unstructured":"NCT02227823 Safety and efficacy study of pyridostigmine on patients with spinal muscular atrophy type 3 www.clinicaltrials.gov\/show\/NCT02227823"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0925-4439(95)00040-B","article-title":"Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies","volume":"1271","author":"Folkers","year":"1995","journal-title":"Biochimica et Biophysica Acta"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/mus.25102","article-title":"Perceived efficacy of salbutamol by persons with spinal muscular atrophy: a mixed methods study","volume":"54","author":"Giovannetti","year":"2016","journal-title":"Muscle & Nerve"},{"issue":"9-10","key":"10.1002\/14651858.CD006282.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.nmd.2014.06.398","article-title":"Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol","volume":"24","author":"Pasanisi","year":"2014","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0027|cit27","unstructured":"NCT03032172 A study of RO7034067 in adult and pediatric participants with spinal muscular atrophy (Jewelfish) clinicaltrials.gov\/show\/NCT03032172"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0028|cit28","unstructured":"JPRN-JapicCTI-163450 Phase 3 study of K-828-SP apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-163450 (first received November 2016)"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/0883073809333535","article-title":"Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy","volume":"24","author":"Kato","year":"2009","journal-title":"Journal of Child Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","article-title":"Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy","volume":"73","author":"Khirani","year":"2017","journal-title":"Pediatric Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL trial part II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PloS One"},{"issue":"1-2","key":"10.1002\/14651858.CD006282.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2007.11.012","article-title":"The effect of hydroxyurea in spinal muscular atrophy cells and patients","volume":"268","author":"Liang","year":"2008","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy","volume":"14","author":"Mercuri","year":"2004","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study","volume":"18","author":"Merlini","year":"2003","journal-title":"Journal of Child Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.33588\/rn.5002.2009267","article-title":"Lamotrigine on motor symptoms of spinal muscular atrophies","volume":"50","author":"Nascimento","year":"2010","journal-title":"Revista de Neurologia"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0037|cit37","first-page":"S128","article-title":"Results of a first-in-human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS-SMNRx in patients with spinal muscular atrophy","volume":"74 Suppl 17","author":"Darras","year":"2013","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0038|cit38","unstructured":"NCT01703988 An open-label safety, tolerability and dose-range finding study of multiple doses of ISIS SMNRx in patients with spinal muscular atrophy (SMNRx - CS2) clinicaltrials.gov\/show\/NCT01703988"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0039|cit39","unstructured":"NCT02052791 An open-label safety and tolerability study of IONIS SMNRx in patients with spinal muscular atrophy who previously participated in IONIS SMNRx-CS2 or IONIS SMNRx-CS10 www.clinicaltrials.gov\/show\/NCT02052791"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0040|cit40","unstructured":"NCT02876094 Effect of low-dose celecoxib on SMN2 in patients with spinal muscular atrophy (SMA) www.clinicaltrials.gov\/show\/NCT02876094"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0041|cit41","unstructured":"NCT03709784 Spinraza in adult spinal muscular atrophy (SAS) clinicaltrials.gov\/ct2\/show\/NCT03709784"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0042|cit42","unstructured":"NCT00439569 Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy types II or III clinicaltrials.gov\/show\/NCT00439569"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0043|cit43","unstructured":"NCT02628743 A study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy clinicaltrials.gov\/show\/NCT02628743"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.2009.200253","article-title":"Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid","volume":"82","author":"Piepers","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0046|cit46","first-page":"S101","article-title":"Long-term open salbutamol trial in spinal muscular atrophy","volume":"257 (Suppl 1)","author":"Prufer de Queiroz Campos Araujo","year":"2010","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ncn3.140","article-title":"A study of valproic acid for patients with spinal muscular atrophy","volume":"3","author":"Saito","year":"2014","journal-title":"Neurology and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0048|cit48","unstructured":"NCT02594124 An open-label study (SHINE) for patients with spinal muscular atrophy (SMA) who participated in studies with IONIS-SMNRx clinicaltrials.gov\/show\/NCT02594124"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0049|cit49","unstructured":"SMART01 Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy dbcentre3.jmacct.med.or.jp\/jmactr\/App\/JMACTRE02_04\/JMACTRE02_04.aspx?kbn=3&seqno=5544 (first received August 2014)"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0050|cit50","unstructured":"SMART03 Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: continuous administration trial dbcentre3.jmacct.med.or.jp\/jmactr\/App\/JMACTRE02_04\/JMACTRE02_04.aspx?kbn=3&seqno=4602 (first received August 2016)"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"Swoboda","year":"2009","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0052|cit52","first-page":"G77(P)","article-title":"Oral salbutamol in 2 wheelchair bound cases of SMA type II","volume":"96 Suppl 1","author":"Tan","year":"2011","journal-title":"Archives of Disease in Childhood"},{"issue":"12","key":"10.1002\/14651858.CD006282.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","article-title":"Valproic acid treatment in six patients with spinal muscular atrophy","volume":"14","author":"Tsai","year":"2007","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy","volume":"67","author":"Weihl","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0055|cit55","unstructured":"NCT00774423 Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI) clinicaltrials.gov\/show\/NCT00774423"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0056|cit56","unstructured":"CHICTR-TRC-10001093 Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial www.chictr.org.cn\/showprojen.aspx?proj=8445"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.nmd.2007.06.071","article-title":"European spinal muscular atrophy RCT of acetyl-L-carnitine in SMA","volume":"17","author":"Merlini","year":"2007","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0058|cit58","unstructured":"NCT02240355 A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) clinicaltrials.gov\/show\/NCT02240355"},{"issue":"10","key":"10.1002\/14651858.CD006282.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.nmd.2013.06.475","article-title":"Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double-blind, placebo-controlled study","volume":"9","author":"Morandi","year":"2013","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0060|cit60","first-page":"97","article-title":"Phase-ll multicenter double-blind, placebo-controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients","volume":"31","author":"Tiziano","year":"2012","journal-title":"Acta Myologica"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0061|cit61","unstructured":"NCT00568802 A pilot therapeutic trial using hydroxyurea in type II and type III spinal muscular atrophy patients clinicaltrials.gov\/show\/NCT00568802"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0062|cit62","unstructured":"NCT01645787 Short and long term treatment with 4-AP in ambulatory SMA patients clinicaltrials.gov\/show\/NCT01645787"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0063|cit63","unstructured":"NCT02644668 A study of CK-2127107 in patients with spinal muscular atrophy clinicaltrials.gov\/show\/NCT02644668"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006282.pub5-BIB0064|cit64","first-page":"P261","article-title":"CK-2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy","volume":"17","author":"Rudnicki","year":"2016","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0065|cit65","unstructured":"SPACE SPACE trial SMA and pyridostigmine in adults and children; experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4 apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-004369-34-NL (first received October 2016)"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0066|cit66","unstructured":"NCT02462759 A study to assess the safety and tolerability of ISIS 396443 (IONIS SMNRx) in participants with spinal muscular atrophy (SMA) (EMBRACE) clinicaltrials.gov\/show\/NCT02462759"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0067|cit67","unstructured":"NCT01671384 Valproate and levocarnitine in children with spinal muscular atrophy clinicaltrials.gov\/show\/NCT01671384"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0068|cit68","unstructured":"SMART02 Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial dbcentre3.jmacct.med.or.jp\/JMACTR\/App\/JMACTRS06\/JMACTRS06.aspx?seqno=5544"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0069|cit69","unstructured":"SUNFISH A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy participants (Sunfish) clinicaltrials.gov\/show\/NCT02908685"},{"issue":"19","key":"10.1002\/14651858.CD006282.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"e88427","DOI":"10.1172\/jci.insight.88427","article-title":"ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice","volume":"1","author":"Abera","year":"2016","journal-title":"JCI Insight"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/ejhg.2011.89","article-title":"Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability","volume":"19","author":"Also-Rallo","year":"2011","journal-title":"European Journal of Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0072|cit72","first-page":"895","article-title":"Advances and challenges in developing a therapy for spinal muscular atrophy","volume":"15","author":"Anderton","year":"2015","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejphar.2017.08.005","article-title":"Edaravone is a candidate agent for spinal muscular atrophy: in vitro analysis using a human induced pluripotent stem cells-derived disease model","volume":"814","author":"Ando","year":"2017","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"European Journal of Human Genetics"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 amplifies skeletal muscle response to nerve activation in humans","volume":"57","author":"Andrews","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1002\/14651858.CD006282.pub5-BIB0076|cit76","first-page":"460","article-title":"Guanidine hydrochloride in infantile and juvenile spinal muscular atrophy. A double blind controlled study","volume":"2","author":"Angelini","year":"1980","journal-title":"Acta Neurologica"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jmg.2007.051177","article-title":"Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells","volume":"45","author":"Angelozzi","year":"2008","journal-title":"Journal of Medical Genetics"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1515\/CCLM.2001.055","article-title":"Neurotrophic factor therapy - prospects and problems","volume":"39","author":"Apfel","year":"2001","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1651-2227.2008.01201.x","article-title":"A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy","volume":"98","author":"Arkblad","year":"2009","journal-title":"Acta Paediatrica"},{"issue":"10","key":"10.1002\/14651858.CD006282.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/labinvest.3700163","article-title":"Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients","volume":"84","author":"Arnold","year":"2014","journal-title":"Laboratory Investigation"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.23995","article-title":"Spinal muscular atrophy: the development and implementation of potential treatments","volume":"74","author":"Arnold","year":"2013","journal-title":"Annals of Neurology"},{"issue":"7454","key":"10.1002\/14651858.CD006282.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"Journal of Clinical Investigation"},{"issue":"12","key":"10.1002\/14651858.CD006282.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI22922","article-title":"Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy","volume":"114","author":"Azzouz","year":"2004","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/mt.2012.261","article-title":"Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice","volume":"21","author":"Benkhelifa-Ziyyat","year":"2013","journal-title":"Molecular Therapy"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nmd.2005.07.005","article-title":"134th ENMC International Workshop: outcome measures and treatment of spinal muscular atrophy, 11-13 February 2005, Naarden, The Netherlands","volume":"15","author":"Bertini","year":"2005","journal-title":"Neuromuscular Disorders"},{"issue":"4481","key":"10.1002\/14651858.CD006282.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.6450446","article-title":"Transport of energy in muscle: the phosphorylcreatine shuttle","volume":"211","author":"Bessman","year":"1981","journal-title":"Science"},{"issue":"6664","key":"10.1002\/14651858.CD006282.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/34651","article-title":"Prostaglandins stimulate calcium-dependent glutamate release in astrocytes","volume":"391","author":"Bezzi","year":"1998","journal-title":"Nature"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0304-3940(02)00667-5","article-title":"Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons","volume":"329","author":"Bigini","year":"2002","journal-title":"Neuroscience Letters"},{"issue":"34","key":"10.1002\/14651858.CD006282.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"12063","DOI":"10.1523\/JNEUROSCI.0608-15.2015","article-title":"IGF-1R Reduction triggers neuroprotective signaling pathways in spinal muscular atrophy mice","volume":"35","author":"Biondi","year":"2015","journal-title":"Journal of Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","article-title":"Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe","volume":"261","author":"Bladen","year":"2014","journal-title":"Journal of Neurology"},{"issue":"43","key":"10.1002\/14651858.CD006282.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"E5863","DOI":"10.1073\/pnas.1509758112","article-title":"Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II\/III spinal muscular atrophy","volume":"112","author":"Bogdanik","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of United States of America"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis","volume":"322","author":"Bordet","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/ph3020345","article-title":"Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound","volume":"3","author":"Bordet","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/hmg\/ddr067","article-title":"Increased IGF-1 in muscle modulates the phenotype of severe SMA mice","volume":"20","author":"Bosch-Marc\u00e9","year":"2011","journal-title":"Human Molecular Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","article-title":"Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model","volume":"19","author":"Bowerman","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"10","key":"10.1002\/14651858.CD006282.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","article-title":"Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy","volume":"7","author":"Bowerman","year":"2012","journal-title":"BMC Medicine"},{"issue":"8951","key":"10.1002\/14651858.CD006282.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(95)90869-2","article-title":"Constitutive muscular abnormalities in culture in spinal muscular atrophy","volume":"345","author":"Braun","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/BF00313933","article-title":"Carnitine and acyltransferase in experimental neurogenic atrophies: changes with treatment","volume":"231","author":"Bresolin","year":"1984","journal-title":"Journal of Neurology"},{"issue":"19","key":"10.1002\/14651858.CD006282.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-199652040-00010","article-title":"Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis","volume":"52","author":"Bryson","year":"1996","journal-title":"Drugs"},{"issue":"6266","key":"10.1002\/14651858.CD006282.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nature Reviews Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.nmd.2012.11.004","article-title":"Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations","volume":"23","author":"Burke","year":"2013","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/hmg\/ddp510","article-title":"Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy","volume":"19","author":"Butchbach","year":"2010","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.expneurol.2016.02.009","article-title":"Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy","volume":"279","author":"Butchbach","year":"2016","journal-title":"Experimental Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/498853","article-title":"Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2","volume":"78","author":"Cartegni","year":"2006","journal-title":"American Journal of Human Genetics"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1249\/00005768-199511000-00002","article-title":"The effects of albuterol and isokinetic exercise on the quadriceps muscle group","volume":"27","author":"Caruso","year":"1995","journal-title":"Medicine and Science in Sports and Exercise"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0306-4522(95)00461-0","article-title":"Prevention by lamotrigine, MK-801 and N omega-nitro-l-arginine methyl ester of motoneuron cell death after neonatal axotomy","volume":"71","author":"Casanovas","year":"1996","journal-title":"Neuroscience"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.biopha.2017.01.104","article-title":"Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells","volume":"88","author":"Chen","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"eCollection 201","DOI":"10.1371\/journal.pone.0185079","article-title":"n vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: context-specific modulation of SMN transcript levels","volume":"12","author":"Cherry","year":"2017","journal-title":"PloS One"},{"issue":"12","key":"10.1002\/14651858.CD006282.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/hmg\/11.12.1439","article-title":"Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model","volume":"11","author":"Cifuentes-Diaz","year":"2002","journal-title":"Human Molecular Genetics"},{"issue":"52","key":"10.1002\/14651858.CD006282.pub5-BIB0113|cit113","first-page":"2525","article-title":"From gene to disease; 'survival' motor neuron protein and hereditary proximal spinal muscle atrophy","volume":"145","author":"Cobben","year":"2001","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006282.pub5-BIB0114|cit114","first-page":"63","article-title":"Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid","volume":"11","author":"Conceicao","year":"2010","journal-title":"Amyotrophic Lateral Sclerosis"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/nbdi.1999.0253","article-title":"Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration","volume":"6","author":"Corse","year":"1999","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2016.11.033","article-title":"The antisense transcript SMN-AS1 regulates SMN expression and Is a novel therapeutic target for spinal muscular atrophy","volume":"93","author":"d'Ydewalle","year":"2017","journal-title":"Neuron"},{"issue":"6","key":"10.1002\/14651858.CD006282.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MOP.0b013e3282f1884c","article-title":"Clinical trials in spinal muscular atrophy","volume":"19","author":"Darras","year":"2007","journal-title":"Current Opinion in Pediatrics"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD006282.pub5-BIB0118|cit118","first-page":"S128","article-title":"Results of a first-in-human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS-SMNRx in patients with spinal muscular atrophy","volume":"74","author":"Darras","year":"2013","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1517\/14712598.2012.711306","article-title":"Update on gene and stem cell therapy approaches for spinal muscular atrophy","volume":"11","author":"Donnelly","year":"2012","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ygcen.2010.04.009","article-title":"Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation","volume":"167","author":"Duan","year":"2010","journal-title":"General and Comparative Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution","volume":"5","author":"Dubowitz","year":"1995","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.24153","article-title":"Performance of the timed \"up & go\" test in spinal muscular atrophy","volume":"50","author":"Dunaway","year":"2014","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JND-160187","article-title":"Effect of the butyrate prodrug pivaloyloxymethyl butyrate (AN9) on a mouse model for spinal muscular atrophy","volume":"3","author":"Edwards","year":"2016","journal-title":"Journal of Neuromuscular Disorders"},{"issue":"14","key":"10.1002\/14651858.CD006282.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00023210-200418140-00002","article-title":"The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders","volume":"18","author":"Ellis","year":"2004","journal-title":"CNS Drugs"},{"issue":"17","key":"10.1002\/14651858.CD006282.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/hmg\/ddt191","article-title":"Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation","volume":"22","author":"Farooq","year":"2013","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"American Journal of Human Genetics"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 November 2014, Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscular Disorders"},{"issue":"10063","key":"10.1002\/14651858.CD006282.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1002\/14651858.CD006282.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nature Biotechnology"},{"issue":"19","key":"10.1002\/14651858.CD006282.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/hmg\/ddm379","article-title":"Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect","volume":"17","author":"Gavrilina","year":"2008","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00019052-199904000-00002","article-title":"Spinal muscular atrophy: molecular pathophysiology","volume":"12","author":"Gendron","year":"1999","journal-title":"Current Opinion in Neurology"},{"issue":"6278","key":"10.1002\/14651858.CD006282.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/345823a0","article-title":"Genetic homogeneity between acute and chronic forms of spinal muscular atrophy","volume":"345","author":"Gilliam","year":"1990","journal-title":"Nature"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2011.11.121","article-title":"Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy","volume":"417","author":"Glascock","year":"2012","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hum.2011.166","article-title":"Decreasing disease severity in symptomatic, SMN(-\/-);SMN2(+\/+), spinal muscular atrophy mice following scAAV9-SMN delivery","volume":"23","author":"Glascock","year":"2012","journal-title":"Human Gene Therapy"},{"issue":"20","key":"10.1002\/14651858.CD006282.pub5-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1093\/hmg\/ddt258","article-title":"The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models","volume":"22","author":"Gogliotti","year":"2013","journal-title":"Human Molecular Genetics"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0960-8966(94)00090-V","article-title":"Possible strategies for treatment of SMA patients: a neurobiologist's view","volume":"5","author":"Greensmith","year":"1995","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.20548","article-title":"Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells","volume":"58","author":"Grzeschik","year":"2005","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"Hach\u00e9","year":"2016","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mus.10455","article-title":"Riluzole attenuates spinal muscular atrophy disease progression in a mouse model","volume":"28","author":"Haddad","year":"2003","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-1172-9-4","article-title":"VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models","volume":"9","author":"Hadwen","year":"2014","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"Journal Neurochemistry"},{"issue":"39","key":"10.1002\/14651858.CD006282.pub5-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proceedings of the National Academy of Sciences in the United States of America"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00415-002-0811-4","article-title":"Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity","volume":"249","author":"Harada","year":"2002","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"5ra12","DOI":"10.1126\/scitranslmed.3000208","article-title":"Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy","volume":"1","author":"Hastings","year":"2009","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/hmg\/ddn357","article-title":"Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition","volume":"18","author":"Hauke","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/hmg\/ddp030","article-title":"Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo","volume":"18","author":"Heier","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0152|cit152","first-page":"107","article-title":"ECG in neonate mice with spinal muscular atrophy allows assessment of drug efficacy","volume":"1","author":"Heier","year":"2015","journal-title":"Frontiers in Bioscience (Elite Edition)"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0153|cit153","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"American Journal of Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1476-5381.2012.01829.x","article-title":"Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice","volume":"166","author":"Hsu","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"15","key":"10.1002\/14651858.CD006282.pub5-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes & Development"},{"issue":"7367","key":"10.1002\/14651858.CD006282.pub5-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.114.222224","article-title":"The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure","volume":"353","author":"Hwee","year":"2015","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0887-8994(93)90082-N","article-title":"Prospective study of spinal muscular atrophy before age 6 years. DCN\/SMA Group","volume":"9","author":"Iannaccone","year":"1993","journal-title":"Pediatric Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2008-1040858","article-title":"Spinal muscular atrophy","volume":"18","author":"Iannaccone","year":"1998","journal-title":"Seminars in Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0161|cit161","first-page":"83","article-title":"Spinal muscular atrophies","volume-title":"Neuromuscular Disorders","author":"Iannaccone","year":"2001"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0162|cit162","first-page":"1657","article-title":"Use of lithium carbonate to treat Kugelberg-Welander spinal amyotrophy","volume":"80","author":"Il'ina","year":"1980","journal-title":"Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia)"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"I37","DOI":"10.1007\/s004150050555","article-title":"The role of SMN in spinal muscular atrophy","volume":"247 Suppl 1","author":"Jablonka","year":"2000","journal-title":"Journal of Neurology"},{"issue":"14","key":"10.1002\/14651858.CD006282.pub5-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","article-title":"Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy","volume":"14","author":"Jarecki","year":"2005","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/13543784.2015.1038341","article-title":"Investigational therapies for the treatment of spinal muscular atrophy","volume":"24","author":"Kaczmarek","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"16","key":"10.1002\/14651858.CD006282.pub5-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1038\/mtna.2014.23","article-title":"A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy","volume":"3","author":"Keil","year":"2014","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuroscience.2007.04.018","article-title":"Anti-glutamatergic effect of riluzole: comparison with valproic acid","volume":"147","author":"Kim","year":"2007","journal-title":"Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00007256-200737020-00001","article-title":"Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes?","volume":"37","author":"Kindermann","year":"2007","journal-title":"Sports Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"Journal of Neuroscience"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/ejpn.2001.0510","article-title":"Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III","volume":"5","author":"Kroksmark","year":"2001","journal-title":"European Journal of Paediatric Neurology"},{"issue":"18","key":"10.1002\/14651858.CD006282.pub5-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1093\/hmg\/ddr288","article-title":"Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice","volume":"20","author":"Kwon","year":"2011","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"10","key":"10.1002\/14651858.CD006282.pub5-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/hmg\/7.10.1531","article-title":"The role of the SMN gene in proximal spinal muscular atrophy","volume":"7","author":"Lefebvre","year":"1998","journal-title":"Human Molecular Genetics"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/hmg\/ddg143","article-title":"Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy","volume":"12","author":"Lesbordes","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11910-011-0240-9","article-title":"New therapeutic approaches to spinal muscular atrophy","volume":"12","author":"Lewelt","year":"2012","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mus.22176","article-title":"Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia","volume":"44","author":"Liewluck","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/mt.2014.209","article-title":"PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy","volume":"23","author":"Little","year":"2015","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"e101225","DOI":"10.1371\/journal.pone.0101225","article-title":"The SMN-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy","volume":"9","author":"Liu","year":"2014","journal-title":"PloS One"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"e0166803","DOI":"10.1371\/journal.pone.0166803","article-title":"Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy","volume":"11","author":"Liu","year":"2016","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jns.2013.05.017","article-title":"Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation","volume":"331","author":"Lorenzoni","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.chembiol.2004.08.024","article-title":"Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism","volume":"11","author":"Lunn","year":"2004","journal-title":"Chemistry & Biology"},{"issue":"9630","key":"10.1002\/14651858.CD006282.pub5-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"e115473","DOI":"10.1371\/journal.pone.0115473","article-title":"Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy","volume":"16","author":"Mack","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1042\/cs0830615","article-title":"Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men","volume":"83","author":"Martineau","year":"1992","journal-title":"Clinical Science (London)"},{"issue":"20","key":"10.1002\/14651858.CD006282.pub5-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","article-title":"Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model","volume":"18","author":"Mattis","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"10","key":"10.1002\/14651858.CD006282.pub5-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2202-10-142","article-title":"Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA","volume":"30","author":"Mattis","year":"2009","journal-title":"BMC Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2012.07.024","article-title":"Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy","volume":"525","author":"Mattis","year":"2012","journal-title":"Neuroscience Letters"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1083\/jcb.200303168","article-title":"Knockdown of the survival motor neuron (SMN) protein in zebrafish causes defects in motor axon outgrowth and pathfinding","volume":"162","author":"McWhorter","year":"2003","journal-title":"Journal of Cell Biology"},{"issue":"6268","key":"10.1002\/14651858.CD006282.pub5-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/344767a0","article-title":"Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q","volume":"344","author":"Melki","year":"1990","journal-title":"Nature"},{"issue":"8710","key":"10.1002\/14651858.CD006282.pub5-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-I","article-title":"Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators","volume":"336","author":"Melki","year":"1990","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006282.pub5-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S1525-0016(16)33289-0","article-title":"Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes","volume":"24","author":"Mendell","year":"2016","journal-title":"Molecular Therapy"},{"issue":"18","key":"10.1002\/14651858.CD006282.pub5-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0198|cit198","first-page":"359","article-title":"Eurosmart: European spinal muscular atrophy randomised trial of acetyl-L-carnitine in spinal muscular atrophy","volume":"166","author":"Merlini","year":"2010","journal-title":"Revue Neurologique"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Molecular Therapy"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/S1415-47572013000300001","article-title":"Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy","volume":"36","author":"Mohseni","year":"2013","journal-title":"Genetics and Molecular Biology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/jhg.2016.61","article-title":"Transcript, methylation and molecular docking analyses of the effects of HDAC inhibitors, SAHA and Dacinostat, on SMN2 expression in fibroblasts of SMA patients","volume":"61","author":"Mohseni","year":"2016","journal-title":"Journal of Human Genetics"},{"issue":"10","key":"10.1002\/14651858.CD006282.pub5-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/0883073813493663","article-title":"Weakness and fatigue in diverse neuromuscular diseases","volume":"28","author":"Montes","year":"2013","journal-title":"Journal of Child Neurology"},{"issue":"5-6","key":"10.1002\/14651858.CD006282.pub5-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26-28 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2119\/molmed.2012.00056","article-title":"IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy","volume":"18","author":"Murdocca","year":"2012","journal-title":"Molecular Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/hmg\/ddm367","article-title":"Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy","volume":"17","author":"Murray","year":"2008","journal-title":"Human Molecular Genetics"},{"issue":"6197","key":"10.1002\/14651858.CD006282.pub5-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0207|cit207","unstructured":"NCT02122952 Gene transfer clinical trial for spinal muscular atrophy type 1 clinicaltrial.gov\/show\/NCT02122952"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0208|cit208","unstructured":"NCT02268552 An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) clinicaltrials.gov\/show\/NCT02268552"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0209|cit209","unstructured":"NCT02633709 A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7034067 (RG7916) given by mouth in healthy volunteers clinicaltrials.gov\/show\/NCT02633709"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.10110","article-title":"Spinal muscular atrophy: recent advances and future prospects","volume":"26","author":"Nicole","year":"2002","journal-title":"Muscle & Nerve"},{"issue":"16","key":"10.1002\/14651858.CD006282.pub5-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/hmg\/ddq226","article-title":"PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons","volume":"19","author":"Ning","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clinthera.2014.02.004","article-title":"Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy \u03947 mouse model phenotype","volume":"36","author":"Nizzardo","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ahg.12031","article-title":"Spinal muscular atrophy: from gene discovery to clinical trials","volume":"77","author":"Nurputra","year":"2013","journal-title":"Annals of Human Genetics"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0214|cit214","unstructured":"NCT02386553 A study of multiple doses of IONIS SMNRx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE) www.clinicaltrials.gov\/show\/NCT02386553"},{"issue":"18","key":"10.1002\/14651858.CD006282.pub5-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/hmg\/ddu198","article-title":"Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models","volume":"23","author":"Osman","year":"2014","journal-title":"Human Molecular Genetics"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/mt.2016.145","article-title":"Optimization of morpholino antisense oligonucleotides targeting the intronic repressor element1 in spinal muscular atrophy","volume":"24","author":"Osman","year":"2016","journal-title":"Molecular Therapy"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0217|cit217","first-page":"9","article-title":"Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol","volume":"24","author":"Pasanisi","year":"2014","journal-title":"Neuromuscular Disorders"},{"issue":"72","key":"10.1002\/14651858.CD006282.pub5-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Science Translational Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0092-8674(00)81632-3","article-title":"A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing","volume":"95","author":"Pellizzoni","year":"1998","journal-title":"Cell"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2012.225","article-title":"Antisense oligonucleotides for the treatment of spinal muscular atrophy","volume":"24","author":"Porensky","year":"2013","journal-title":"Human Gene Therapy"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0222|cit222","unstructured":"RAINBOWFISH A study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (Rainbowfish) clinicaltrials.gov\/ct2\/show\/NCT03779334"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0223|cit223","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00439-006-0186-1","article-title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA\/protein levels in spinal muscular atrophy cells","volume":"120","author":"Riessland","year":"2006","journal-title":"Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","article-title":"SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy","volume":"19","author":"Riessland","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"American Journal of Human Genetics"},{"issue":"17","key":"10.1002\/14651858.CD006282.pub5-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","article-title":"Defining the therapeutic window in a severe animal model of spinal muscular atrophy","volume":"23","author":"Robbins","year":"2014","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0228|cit228","unstructured":"Jethwa S on behalf of the Roche SMA Team www.treatsma.uk\/wp-content\/uploads\/2018\/05\/2018-05-30-Olesoxime-PG-update-May-2018.pdf"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","article-title":"Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes","volume":"85","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons","volume":"163","author":"Rossoll","year":"2003","journal-title":"Journal of Cell Biology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0231|cit231","first-page":"214","article-title":"CK-2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy","volume":"17","author":"Rudnicki","year":"2016","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/088307389200700403","article-title":"Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema","volume":"7","author":"Russman","year":"1992","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.47.4.973","article-title":"Function changes in spinal muscular atrophy II and III. The DCN\/SMA Group","volume":"47","author":"Russman","year":"1996","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A phase 1 trial of riluzole in spinal muscular atrophy","volume":"60","author":"Russman","year":"2003","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006282.pub5-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ejhg.2012.222","article-title":"Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585","volume":"21","author":"Schreml","year":"2013","journal-title":"European Journal of Human Genetics"},{"issue":"12","key":"10.1002\/14651858.CD006282.pub5-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.bbadis.2013.08.005","article-title":"Spinal muscular atrophy: an update on therapeutic progress","volume":"1832","author":"Seo","year":"2013","journal-title":"Biochimica Biophysica Acta"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/hum.2010.114","article-title":"Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy","volume":"22","author":"Shababi","year":"2011","journal-title":"Human Gene Therapy"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12031-011-9614-3","article-title":"Optimization of SMN trans-splicing through the analysis of SMN introns","volume":"46","author":"Shababi","year":"2012","journal-title":"Journal Molecular Neuroscience"},{"issue":"11","key":"10.1002\/14651858.CD006282.pub5-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1021\/cb800120t","article-title":"DcpS as a therapeutic target for spinal muscular atrophy","volume":"3","author":"Singh","year":"2008","journal-title":"ACS Chemical Biology"},{"issue":"7","key":"10.1002\/14651858.CD006282.pub5-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","article-title":"Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts","volume":"100","author":"Skordis","year":"2003","journal-title":"Proceedings of National Academy of Sciences of the United States of America"},{"issue":"Suppl 20","key":"10.1002\/14651858.CD006282.pub5-BIB0241|cit241","first-page":"S368","article-title":"Interim safety, efficacy and achievement of developmental milestones in this phase 1, first-in-human study of the systemic delivery of AVXS-101, an AAV9-mediated gene therapy for children with spinal muscular atrophy (SMA) type 1","volume":"80","author":"Sproule","year":"2016","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ygeno.2015.01.007","article-title":"Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7","volume":"105","author":"Staropoli","year":"2015","journal-title":"Genomics"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0243|cit243","first-page":"3","article-title":"Spinal muscular atrophy disease: a literature review for therapeutic strategies","volume":"3","author":"Stavarachi","year":"2010","journal-title":"Journal of Medicine and Life"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0244|cit244","unstructured":"STOPSMA Study to evaluate sodium phenylbutyrate in pre-symptomatic infants with spinal muscular atrophy (STOPSMA) clinicaltrials.gov\/show\/NCT00528268"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0245|cit245","unstructured":"STRONG Study of intrathecal administration of AVXS-101 for spinal muscular atrophy (STRONG) clinicaltrials.gov\/ct2\/show\/NCT03381729"},{"issue":"Suppl 20","key":"10.1002\/14651858.CD006282.pub5-BIB0246|cit246","first-page":"S293","article-title":"The SMN2 splicing modifier RG7916 induces a dose-dependent increase of full length SMN2 mRNA","volume":"80","author":"Sturm","year":"2016","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0883073807305787","article-title":"Molecular mechanisms of spinal muscular atrophy","volume":"22","author":"Sumner","year":"2007","journal-title":"Journal of Child Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0883073807305665","article-title":"Perspectives on clinical trials in spinal muscular atrophy","volume":"22","author":"Swoboda","year":"2007","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/088307389400900313","article-title":"Efficacy of thyrotropin-releasing hormone in the treatment of spinal muscular atrophy","volume":"9","author":"Takeuchi","year":"1994","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1023\/A:1005516625866","article-title":"Spinal muscular atrophy","volume":"22","author":"Talbot","year":"1999","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1212\/WNL.52.4.854","article-title":"Creatine monohydrate increases strength in patients with neuromuscular disease","volume":"52","author":"Tarnopolsky","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A summary of mechanistic hypotheses of gabapentin pharmacology","volume":"29","author":"Taylor","year":"1998","journal-title":"Epilepsy Research"},{"issue":"5-6","key":"10.1002\/14651858.CD006282.pub5-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0960-8966(94)90090-6","article-title":"The natural history of type I (severe) spinal muscular atrophy","volume":"4","author":"Thomas","year":"1994","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/jm061475p","article-title":"Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy","volume":"51","author":"Thurmond","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/hmg\/ddl482","article-title":"Stat5 constitutive activation rescues defects in spinal muscular atrophy","volume":"16","author":"Ting","year":"2007","journal-title":"Human Molecular Genetics"},{"issue":"23","key":"10.1002\/14651858.CD006282.pub5-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","article-title":"Disease mechanisms and therapeutic approaches in spinal muscular atrophy","volume":"35","author":"Tisdale","year":"2015","journal-title":"Journal of Neuroscience"},{"issue":"12","key":"10.1002\/14651858.CD006282.pub5-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design","volume":"47","author":"Tiziano","year":"2010","journal-title":"Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.nbd.2011.06.021","article-title":"IGF-1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice","volume":"45","author":"Tsai","year":"2012","journal-title":"Neurobiology of Disease"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2014.84","article-title":"Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice","volume":"22","author":"Tsai","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.phrs.2016.05.023","article-title":"Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt\/mTOR in experimental models of spinal muscular atrophy","volume":"111","author":"Tseng","year":"2016","journal-title":"Pharmacological Research"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cbin.10395","article-title":"Effects of flavonoid quercetin on survival of motor neuron gene expression","volume":"39","author":"Uzunalli","year":"2015","journal-title":"Cell Biology International"},{"issue":"35","key":"10.1002\/14651858.CD006282.pub5-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Science Translational Medicine"},{"issue":"20","key":"10.1002\/14651858.CD006282.pub5-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1093\/hmg\/ddt257","article-title":"The DcpS inhibitor RG3039 improves motor function in SMA mice","volume":"22","author":"Meerbeke","year":"2013","journal-title":"Human Molecular Genetics"},{"issue":"20","key":"10.1002\/14651858.CD006282.pub5-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","article-title":"Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3","volume":"79","author":"Wadman","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4","volume":"88","author":"Wadman","year":"2017","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD006282.pub5-BIB0268|cit268","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006281.pub5","article-title":"Drug treatment for spinal muscular atrophy type I","author":"Wadman","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006282.pub5-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.spen.2006.06.008","article-title":"Spinal muscular atrophy: from gene to therapy","volume":"13","author":"Wirth","year":"2006","journal-title":"Seminars in Pediatric Neurology"},{"key":"10.1002\/14651858.CD006282.pub5-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-540-34449-0_6","article-title":"Spinal muscular atrophy and therapeutic prospects","volume":"44","author":"Wirth","year":"2006","journal-title":"Progress in Molecular and Subcellular Biology"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Dysregulation of ubiquitin homeostasis and \u03b2-catenin signaling promote spinal muscular atrophy","volume":"124","author":"Wishart","year":"2014","journal-title":"Journal of Clinical Investigation"},{"issue":"13","key":"10.1002\/14651858.CD006282.pub5-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1021\/acs.jmedchem.6b00460","article-title":"Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 as a treatment for spinal muscular atrophy","volume":"59","author":"Woll","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1002\/14651858.CD006282.pub5-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/hmg\/ddi131","article-title":"A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels","volume":"14","author":"Wolstencroft","year":"2005","journal-title":"Human Molecular Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006282.pub5-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"E1509","DOI":"10.1073\/pnas.1616521114","article-title":"Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy","volume":"114","author":"Woo","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ana.21241","article-title":"5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells","volume":"63","author":"Yuo","year":"2008","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clinthera.2013.11.006","article-title":"Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials","volume":"36","author":"Zanetta","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD006282.pub5-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0960-8966(99)00016-4","article-title":"59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The Netherlands","volume":"9","author":"Zerres","year":"1999","journal-title":"Neuromuscular Disorders"},{"issue":"20","key":"10.1002\/14651858.CD006282.pub5-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.gt.3301550","article-title":"An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA","volume":"8","author":"Zhang","year":"2001","journal-title":"Gene Therapy"},{"issue":"3","key":"10.1002\/14651858.CD006282.pub5-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/hum.2012.211","article-title":"A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice","volume":"24","author":"Zhou","year":"2013","journal-title":"Human Gene Therapies"},{"issue":"22","key":"10.1002\/14651858.CD006282.pub5-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/hmg\/ddv329","article-title":"Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response","volume":"24","author":"Zhou","year":"2015","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.bbrc.2007.10.096","article-title":"SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity","volume":"364","author":"Zou","year":"2007","journal-title":"Biochemical and Biophysical Research Communication"},{"issue":"1","key":"10.1002\/14651858.CD006282.pub5-BIB0284|cit284","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006282.pub2","article-title":"Drug treatment for spinal muscular atrophy types II and III","author":"Bosboom","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006282.pub5-BIB0285|cit285","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006282.pub4","article-title":"Drug treatment for spinal muscular atrophy types II and III","author":"Wadman","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006282.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:57:24Z","timestamp":1628546244000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006282.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":285,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006282.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]}}}